Target- |
Mechanism- |
|
|
|
Inactive Indication- |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.Japan |
First Approval Date17 Jun 1994 |
100 Clinical Results associated with Tamagawa Eizai Co. Ltd.
0 Patents (Medical) associated with Tamagawa Eizai Co. Ltd.
100 Deals associated with Tamagawa Eizai Co. Ltd.
100 Translational Medicine associated with Tamagawa Eizai Co. Ltd.